Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

Zuzana Berrong, Mikayel Mkrtichyan, Shamim Ahmad, Mason Webb, Eslam Mohamed, Grigori Okoev, Adelaida Matevosyan, Rajeev Shrimali, Rasha Abu Eid, Scott Hammond, John E Janik, Samir N Khleif

Research output: Contribution to journalArticle

2 Citations (Scopus)
5 Downloads (Pure)

Abstract

Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO- TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60% of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40, and (ii) a decrease of IDO enzyme activity produced by non-tumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.

Original languageEnglish
Pages (from-to)201-208
Number of pages8
JournalCancer immunology research
Volume6
Issue number2
Early online date5 Jan 2018
DOIs
Publication statusPublished - Feb 2018

Fingerprint

Antigens
Neoplasms
Vaccines
Immunotherapy
Indoleamine-Pyrrole 2,3,-Dioxygenase
T-Lymphocytes
Cancer Vaccines
Tumor Microenvironment
1-methyltryptophan
Histocompatibility Antigens Class II
Immunosuppressive Agents
Immunity
Therapeutics
Enzymes

Keywords

  • Journal Article

Cite this

Berrong, Z., Mkrtichyan, M., Ahmad, S., Webb, M., Mohamed, E., Okoev, G., ... Khleif, S. N. (2018). Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod. Cancer immunology research, 6(2), 201-208. https://doi.org/10.1158/2326-6066.CIR-17-0223

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod. / Berrong, Zuzana; Mkrtichyan, Mikayel; Ahmad, Shamim; Webb, Mason; Mohamed, Eslam; Okoev, Grigori; Matevosyan, Adelaida; Shrimali, Rajeev; Abu Eid, Rasha; Hammond, Scott; Janik, John E; Khleif, Samir N.

In: Cancer immunology research, Vol. 6, No. 2, 02.2018, p. 201-208.

Research output: Contribution to journalArticle

Berrong, Z, Mkrtichyan, M, Ahmad, S, Webb, M, Mohamed, E, Okoev, G, Matevosyan, A, Shrimali, R, Abu Eid, R, Hammond, S, Janik, JE & Khleif, SN 2018, 'Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod' Cancer immunology research, vol. 6, no. 2, pp. 201-208. https://doi.org/10.1158/2326-6066.CIR-17-0223
Berrong, Zuzana ; Mkrtichyan, Mikayel ; Ahmad, Shamim ; Webb, Mason ; Mohamed, Eslam ; Okoev, Grigori ; Matevosyan, Adelaida ; Shrimali, Rajeev ; Abu Eid, Rasha ; Hammond, Scott ; Janik, John E ; Khleif, Samir N. / Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod. In: Cancer immunology research. 2018 ; Vol. 6, No. 2. pp. 201-208.
@article{dccfdae2f40f4a39845b2ddf05bc90c0,
title = "Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod",
abstract = "Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO- TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60{\%} of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40, and (ii) a decrease of IDO enzyme activity produced by non-tumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.",
keywords = "Journal Article",
author = "Zuzana Berrong and Mikayel Mkrtichyan and Shamim Ahmad and Mason Webb and Eslam Mohamed and Grigori Okoev and Adelaida Matevosyan and Rajeev Shrimali and {Abu Eid}, Rasha and Scott Hammond and Janik, {John E} and Khleif, {Samir N}",
note = "Published article becomes freely available online after 12 months",
year = "2018",
month = "2",
doi = "10.1158/2326-6066.CIR-17-0223",
language = "English",
volume = "6",
pages = "201--208",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

AU - Berrong, Zuzana

AU - Mkrtichyan, Mikayel

AU - Ahmad, Shamim

AU - Webb, Mason

AU - Mohamed, Eslam

AU - Okoev, Grigori

AU - Matevosyan, Adelaida

AU - Shrimali, Rajeev

AU - Abu Eid, Rasha

AU - Hammond, Scott

AU - Janik, John E

AU - Khleif, Samir N

N1 - Published article becomes freely available online after 12 months

PY - 2018/2

Y1 - 2018/2

N2 - Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO- TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60% of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40, and (ii) a decrease of IDO enzyme activity produced by non-tumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.

AB - Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO- TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60% of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40, and (ii) a decrease of IDO enzyme activity produced by non-tumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.

KW - Journal Article

U2 - 10.1158/2326-6066.CIR-17-0223

DO - 10.1158/2326-6066.CIR-17-0223

M3 - Article

VL - 6

SP - 201

EP - 208

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 2

ER -